INTRODUÇÃO: O bócio é um termo genérico usado para descrever o aumento no volume da glândula tireoide que pode estar associado à formação de múltiplos nódulos, o chamado bócio multinodular. Camundongos transgênicos tireoide específicos com depleção do Pten ou aumento de expressão do Dream, dois importantes genes que têm sido implicados nas vias de sinalização das células foliculares, apresentam desenvolvimento de bócio. Em humanos, uma larga porcentagem de pacientes com doença de Cowden apresentam bócio ou outras anormalidades tireoidianas associadas a mutações germinativas no PTEN. OBJETIVO: O objetivo desse estudo foi investigar a expressão dos genes PTEN e DREAM em tecido hiperplásico tireoidiano, bem como mutações germinativas e somáticas no PTEN e mutações somáticas no DREAM, em pacientes portadores de bócio multinodular, com a finalidade de avaliar o papel destes genes na etiologia do bócio. MÉTODOS: Foram investigados 60 pacientes com bócio multinodular (54 mulheres). A extração do DNA genômico foi realizada a partir de tecido hiperplásico da tireoide e do sangue periférico dos pacientes enquanto o RNA foi obtido apenas do tecido glandular. A quantificação relativa do RNA mensageiro do PTEN e do DREAM foi avaliada pelo método de 2-??Ct utilizando o GAPDH como normalizador em dados produzidos pela PCR em tempo real. A alta e a baixa expressão de PTEN e DREAM foram definidas, respectivamente, por valores de quantificação superiores a 2.0 e inferiores a 0.5 em comparação a um pool comercial de RNA de tireoide normal de humanos. Análise de mutação foi realizada por amplificação da região codificante dos genes PTEN e DREAM pela PCR convencional seguida por sequenciamento automático (RQ = quantificação relativa; x? = média e DP = desvio padrão). RESULTADOS: Foi observada alta expressão do PTEN em 58,3% dos pacientes portadores de bócio (x RQ = 3,81; DP = 2,26) enquanto apenas dois casos apresentaram baixa expressão (x? RQ = 0,34; DP= 0,09). Nos 38,3% casos restantes foi observada expressão normal de PTEN (x? RQ = 1,35; DP = 0,35). Em relação ao gene DREAM, alta e baixa expressão foram observadas em 33,3% (x RQ = 6,07; DP = 5,02) e 15,0% (x RQ = 0,30; DP = 0,10) dos pacientes com bócio respectivamente, enquanto pouco mais da metade dos casos (51,6%) teve expressão normal RQ = 1,12 ; DP = 0,40). A Análise de mutações do PTEN e do DREAM revelaram apenas polimorfismos intrônicos, previamente descritos no banco de dados do NCBI, tanto nos DNA de sangue e/ou de tecido hiperplásico. CONCLUSÕES: Nossos resultados demonstraram uma expressão aumentada de PTEN em bócio multinodular, sugerindo que este pode estar hiperexpresso, ou pelo menos tem sua expressão mantida, nesta hiperplasia benigna da tireoide. Alterações na sequência gênica codificante do PTEN não foram observadas. Na análise mutacional e de expressão do DREAM não foram encontradas alterações que pudessem ser relacionadas à patogênese de bócio em humanos / BACKGROUND: Multinodular goiter is a clinicopathological entity characterized by an increased volume of the thyroid gland with formation of nodules. A high proliferative status of thyroid follicular cells and goiter were observed in mutants mice with specifically deleted Pten or Dream overexpression in thyrocytes. In humans, a large percentage of patients with Cowden disease have goiters or other thyroid abnormalities associated with germ-line PTEN mutations. OBJECTIVE: The aim of this study was to investigate the tissue expression of PTEN and DREAM, as well as germ-line and somatic PTEN mutations and somatic DREAM mutations, in patients with multinodular goiter to evaluated the role of these genes in goitrogenesis. METHODS: We investigated 60 multinodular goiter patients (54 females). Genomic DNA was extracted from both patients\' hyperplastic thyroid tissue and peripheral blood whereas RNA was obtained only from glandular tissue. Relative quantification of PTEN and DREAM messenger RNA was evaluated using 2-Ct method normalized to GAPDH expression on data produced by real-time PCR. PTEN and DREAM over and lower expression were respectively defined by value > 2.0-fold and < 0.5-fold relative to a commercial pool of normal human thyroid RNA. Mutations analyses were performed by amplification of PTEN and DREAM coding region by PCR followed by automatic sequencing. RQ = relative quantification; x = average; SD = standard deviation. RESULTS: We observed a high expression of PTEN in 58.3% of multinodular goiter patients (RQ x = 3.81; SD = 2.26) and only two cases with lower expression (RQ x = 0.34; SD = 0.09). In the remaining 38.3% of patients expression of PTEN was normal (RQ x = 1.35; SD = 0.35). For the DREAM, over and lower expression were observed in 33.3% (RQ x = 6.07; SD = 5.02) and 15.0% (RQ x = 0.30; SD = 0.10) of patients respectively, whereas 51.6% had normal expression (RQ x = 1.12; SD = 0.40). Regarding PTEN and DREAM mutations analysis, only previously described intronic polymorphisms were observed in DNA from blood and/or thyroid hyperplastic tissue. CONCLUSIONS: Our results demonstrated that PTEN expression is higher in multinodular goiter suggesting that this gene is overregulated (or at least has its expression maintained) in this benign hyperplastic thyroid lesions. No evidence for the involvement of DREAM in goitrogenesis was observed in our cohort of multinodular goiter patients

No description available.

A steady state level of negative supercoiling is essential for chromosome condensation, initiation of replication and subsequent elongation step. DNA gyrase, found in every eubacteria, serves the essential housekeeping function of maintenance of the negative supercoiling status of the genome. The functional holoenzyme is a heterotetramer, comprising of two GyrA and two GyrB subunits. DNA gyrase is an indispensable enzyme and serves as a readily susceptible target for natural antibacterial agents. The enzymatic steps of topoisomerisation by gyrase involve transient double strand break and rejoining of the strands after intact duplex transfer. Corruption of its catalytic cycle can lead to the generation of cytotoxic double-strand DNA breaks. Most of the anti-gyrase agents achieve their objective by targeting the vulnerable step of the reaction cycle i.e. DNA cleavage step. Bacteria on their part must have evolved and adopted strategies to counter the action of external agents and prevent the generation of double strand breaks thereby safeguarding their genome. In the present thesis, attempts have been made to understand the role of three endogenous gyrase interacting proteins in gyrase modulation and cellular defense against anti-gyrase agents. The thesis is divided into six chapters. Chapter 1 introduces the wonder enzymes “DNA topoisomerases” starting with a brief classification of these enzymes and their physiological functions. In the next section, DNA gyrase has been discussed in greater detail. The structural aspects as well as the mechanism of the topoisomerisation reaction catalyzed by gyrase have been discussed. Final section gives an overview of different gyrase modulators known till date focusing on their source, structure and mode of action. The scope and objectives of the present study is presented at the end of this chapter. In Chapter 2 is aimed at understanding the physiological role of GyrI. GyrI, originally identified in Escherichia coli as an inhibitor of DNA gyrase, has been previously shown in the laboratory to render protection against gyrase poisons and also various other DNA damaging agents (mitomycin C, MNNG). Abolishing GyrI expression renders the cell hypersensitive to these cytotoxic agents. Interestingly, GyrI exhibits contrasting behavior towards two plasmid encoded proteinaceous poisons of DNA gyrase. It reduces microcin B17-mediated double-strand breaks in vivo, imparting protection to the cells against the toxin. However, a positive cooperation between GyrI and F plasmid encoded toxin CcdB, results in enhanced DNA damage and cell death. These results suggest a more complex functional interplay and physiological role for GyrI. Search for other chromosomally encoded gyrase inhibitors led to YacG, a small zinc finger protein (7.3kDa) from E. coli, shown to be a member of DNA gyrase interactome, in a protein-protein interaction network described recently. Chapter 3 deals with the detailed characterization of YacG. It is shown that YacG inhibits DNA gyrase by binding to GyrB subunit and preventing DNA binding activity of the enzyme. More importantly, it protects against the cytotoxic effects of other gyrase inhibitors like ciprofloxacin, novobiocin, microcin B17 and CcdB. Further investigations revealed that YacG and its homologues are found only in proteobacteria. Hence, it appears to be a defense strategy developed by gram-negative bacteria to fight against the gyrase targeting cytotoxic agents. Inhibition by YacG appears to be specific to E. coli gyrase as mycobacterial enzyme is refractile to YacG action. GyrB, only in gram-negative organisms, possesses extra stretch of 165 amino acids, indispensable for DNA binding. Biochemical experiments with the truncated GyrB lacking the extra stretch reveal the importance of this stretch for stable YacG-GyrB interaction. E. coli topoisomerase IV is also resistant to YacG mediated inhibition, probably due to the absence of the extra stretch in ParE subunit, which is otherwise highly similar to GyrB. Further, YacG homologues from other proteobacterial members (Sinorhizobium meliloti and Haemophilus influenzae homologues sharing 35% and 63 % identity with E. coli YacG respectively ) also inhibits E. coli DNA gyrase at comparable levels. YacG thus emerges as a proteobacteria specific inhibitor of DNA gyrase. The occurrence of both YacG and the gyrase extra stretch only in proteobacteria, suggest co-evolution of interacting partners in proteobacteria. In Chapter 4, the study of endogenous gyrase modulators is extended to Mycobacterium sp. glutamate racemase (MurI) from E. coli has been shown earlier to be an inhibitor of DNA gyrase. However, nothing much was known about its mode of action. MurI is an important enzyme in the cell wall biosynthesis pathway, which catalyses the conversion of L-glutamate to D-glutamate, an integral component of the bacterial cell wall. In this chapter, it is demonstrated that M. tuberculosis MurI inhibits DNA gyrase activity, in addition to its precursor independent racemization function. The inhibition is not species specific as E. coli gyrase is also inhibited. However, it is gyrase specific as topoisomerase I activity remains unaltered. The mechanism of inhibition by MurI has been elucidated for the first time and it is shown that MurI binds to GyrA subunit of the enzyme leading to a decrease in DNA binding of the holoenzyme. The sequestration of the gyrase by MurI results in inhibition of all reactions catalyzed by DNA gyrase. Chapter 5 is the extension of the studies on glutamate racemase into another species, i.e. Mycobacterium smegmatis. DNA gyrase inhibition seems to be an additional attribute of some of the glutamate racemases, but not all, as Glr isozyme from B. subtilis has no effect on gyrase activity in spite of sharing a high degree of similarity with the gyrase inhibitory glutamate racemases. It is shown that like the M. tuberculosis MurI, M. smegmatis enzyme is also a bifunctional enzyme. It inhibits DNA gyrase in addition to its racemization activity. Further, overexpression of the enzyme in M. smegmatis provides protection to the organism against fluoroquinolones. DNA gyrase inhibitory property thus appears to be a typical characteristic of these MurI and seems to have evolved to either modulate the function of the essential housekeeping enzyme or to provide protection to gyrase against gyrase inhibitors, which cause double strand breaks in the genome. In the above chapters, it is shown that besides its crucial role in cell wall biosynthesis, mycobacterial MurI moon lights as DNA gyrase inhibitor. That the two activities exhibited by M. tuberculosis MurI are unlinked and independent of each other is demonstrated in Chapter 6. Racemization function of MurI is not essential for its gyrase inhibitory property as mutants compromised in racemization activity retain gyrase inhibition property. MurI- DNA gyrase interaction influences gyrase activity but has no effect on racemization activity of MurI. MurI expression in mycobacterial cells provides protection against the action of ciprofloxacin, thereby suggesting a role of MurI in countering external agents targeting DNA gyrase. Further M. tuberculosis MurI overexpressed in near homologous expression system of M. smegmatis yields highly soluble enzyme which can be further used for structural and functional studies. In conclusion, the studies reveal that the endogenous inhibitors essentially influence the enzyme activity by sequestering the enzyme away from DNA. None of them cause cytotoxicity, which usually arises as a result of DNA damage caused by accumulation of gyrase-DNA covalent intermediate. On the contrary they provide protection against such gyrase poisons. Comparative analysis of these proteinaceous inhibitors, however, does not reveal a common motif or structural fold, required for their ability to inhibit DNA gyrase. Based on these studies, it can be proposed that these endogenous proteins exist to serve as cellular defense strategies against external abuse and also to modulate the intracellular activity of DNA gyrase as and when required, for accurate division, functioning and survival of the cells.